Mixing particles from various HCV genotypes increases the HBV‐HCV vaccine ability to elicit broadly cross‐neutralizing antibodies
- 27 May 2020
- journal article
- research article
- Published by Wiley in Liver International
- Vol. 40 (8) , 1865-1871
Abstract
The development of a safe, effective and affordable prophylactic vaccine against hepatitis C virus (HCV) remains a medical priority. Hepatitis B‐C subviral envelope particles, which could be produced by industrial procedures adapted from those established for the hepatitis B virus vaccine, appear promising for use for this purpose. The prototype HBV‐HCV bivalent vaccine‐bearing genotype 1a HCV envelopes can induce neutralizing antibodies against this genotype, but is less effective against other genotypes. We show here, in a small animal model, that the use of a set of vaccine particles harbouring envelopes from different HCV genotypes in various association strategies can induce broad neutralizing protection or an optimized protection against a particular genotype prevalent in a given region, such as genotype 4 in Egypt. This vaccine could help to control the hepatitis C epidemic worldwide.Keywords
Funding Information
- Conseil Régional du Centre-Val de Loire (ARD2020 Biomédicaments)
- Krebsliga Schweiz
- Agence Nationale de Recherches sur le Sida et les Hépatites Virales
This publication has 19 references indexed in Scilit:
- Can Broadly Neutralizing Monoclonal Antibodies Lead to a Hepatitis C Virus Vaccine?Trends in Microbiology, 2018
- Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agenciesVirus Research, 2018
- Hepatitis C virus resistance to broadly neutralizing antibodies measured using replication-competent virus and pseudoparticlesJournal of General Virology, 2016
- HCV epidemiology in high-risk groups and the risk of reinfectionJournal of Hepatology, 2016
- A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization ResistanceJournal of Virology, 2016
- Hepatitis C Virus E1 and E2 Proteins Used as Separate Immunogens Induce Neutralizing Antibodies with Additive PropertiesPLOS ONE, 2016
- Breadth of neutralization and synergy of clinically relevant human monoclonal antibodies against HCV genotypes 1a, 1b, 2a, 2b, 2c, and 3aHepatology, 2014
- Chimeric hepatitis B virus/hepatitis C virus envelope proteins elicit broadly neutralizing antibodies and constitute a potential bivalent prophylactic vaccineHepatology, 2012
- Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virusProceedings of the National Academy of Sciences, 2012
- Chimeric hepatitis B and C viruses envelope proteins can form subviral particles: implications for the design of new vaccine strategiesNew Biotechnology, 2009